228 related articles for article (PubMed ID: 24100922)
1. Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.
Sasaki H; Ishida K; Shibanuma N; Tei K; Tateishi H; Toda A; Yamashiro Y; Matsumoto T; Kuroda R; Kurosaka M
Int Orthop; 2014 Mar; 38(3):525-9. PubMed ID: 24100922
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Migita K; Bito S; Nakamura M; Miyata S; Saito M; Kakizaki H; Nakayama Y; Matsusita T; Furuichi I; Sasazaki Y; Tanaka T; Yoshida M; Kaneko H; Abe I; Mine T; Ihara K; Kuratsu S; Saisho K; Miyahara H; Segata T; Nakagawa Y; Kamei M; Torigoshi T; Motokawa S
Arthritis Res Ther; 2014 Jul; 16(4):R154. PubMed ID: 25047862
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
4. Safety of fondaparinux versus enoxaparin after TKA in Japanese patients.
Hosaka K; Saito S; Ishii T; Sumino T; Ryu K; Suzuki G; Suzuki T; Tokuhashi Y
Orthopedics; 2013 Apr; 36(4):e428-33. PubMed ID: 23590781
[TBL] [Abstract][Full Text] [Related]
5. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Fuji T; Fujita S; Tachibana S; Kawai Y
J Thromb Haemost; 2010 Nov; 8(11):2458-68. PubMed ID: 20723033
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
[TBL] [Abstract][Full Text] [Related]
8. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
[TBL] [Abstract][Full Text] [Related]
9. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
10. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Feng W; Wang X; Huang D; Lu A
Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty.
Kodato K; Ishida K; Shibanuma N; Toda A; Takayama K; Oka S; Hayashi S; Hashimoto S; Kurosaka M; Kuroda R; Matsumoto T
Eur J Orthop Surg Traumatol; 2018 Jan; 28(1):103-108. PubMed ID: 28766070
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Bauer KA; Eriksson BI; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1305-10. PubMed ID: 11794149
[TBL] [Abstract][Full Text] [Related]
13. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
15. The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial.
Steele KE; Canner J; Prokopowicz G; Verde F; Beselman A; Wyse R; Chen J; Streiff M; Magnuson T; Lidor A; Schweitzer M
Surg Obes Relat Dis; 2015; 11(3):672-83. PubMed ID: 25620436
[TBL] [Abstract][Full Text] [Related]
16. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Doggrell SA
Expert Opin Pharmacother; 2002 Apr; 3(4):455-7. PubMed ID: 11934350
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.
Hur M; Park SK; Koo CH; Jung ED; Kang P; Kim WH; Kim JT; Jung CW; Bahk JH
Acta Orthop; 2017 Dec; 88(6):634-641. PubMed ID: 28787226
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Turpie AG
Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
[TBL] [Abstract][Full Text] [Related]
19. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
Ishida K; Shibanuma N; Kodato K; Toda A; Sasaki H; Takayama K; Hayashi S; Hashimoto S; Matsushita T; Niikura T; Kurosaka M; Kuroda R; Matsumoto T
J Orthop Sci; 2018 Nov; 23(6):1005-1010. PubMed ID: 30431004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
